Case Acceptance vs New Patient Volume: The Cheaper Lever

Raising case acceptance is almost always the cheaper lever, because the patient is already acquired and the treatment is already diagnosed. New patient volume is the right lever only when the schedule is genuinely empty. Most cosmetic practices with soft production are not short on patients, they are short on yes.

That distinction costs practices real money every quarter, because the reflex when production dips is to buy more patients. This post puts both levers side by side with current numbers and argues for the one most owners reach for last.

Which grows a cosmetic practice faster, more new patients or higher case acceptance?

Start with what each lever asks of you. Buying new patients asks for cash today and produces a patient who still has to say yes to treatment. Raising acceptance asks for a change in how the consult runs and produces revenue from treatment you have already diagnosed and already paid to diagnose.

The demand picture matters here. In the ADA Health Policy Institute's Q4 2025 poll, reported in February 2026, 33 percent of dentists said they were not busy enough, and the average wait for a new patient appointment was 13.4 days. That same poll put overhead at 42.3 percent for non-DSO dentists and 35.2 percent for DSO-affiliated practices. Read those together and you get the shape of the problem. Chairs have room, overhead is heavy, and every dollar of new spend has to clear a high bar before it turns into profit.

What does a new dental patient actually cost in 2026?

More than most owners think, and far more than the alternative sitting in their own charts.

Current 2026 benchmarks put the cost of acquiring a new dental patient near $312, against roughly $12 to reactivate a patient the practice already has. That is not a rounding difference. That is two different businesses.

The spread by specialty is even wider. General dentistry acquisition runs near $200 per patient. Cosmetic prosthodontics can run toward $1,800. If you sell high-ticket cosmetic work, you are shopping in the most expensive aisle in dentistry.

The reason is structural, not a failure of your marketing. The consideration window is long, nobody decides on veneers between two meetings. The competition is bidding on the same high-intent searches you are. It takes more touches before a booking, and each touch costs.

So a cosmetic practice pays a premium to get someone into the chair. Which makes what happens next the most expensive part of the whole operation to get wrong.

Why is unaccepted treatment cheaper revenue than a new patient?

Because you have already paid for it twice.

You paid the acquisition cost to get that patient through the door. Then you paid in chair time, clinical judgment, imaging, and the doctor's attention to diagnose the treatment. Both of those costs are sunk the moment the patient walks out undecided. The diagnosis is the expensive half of the sale, and on an unaccepted case it is already complete.

What is left is the cheap half. The patient understanding what you found, believing the result is worth it, and deciding now rather than someday.

The math also scales differently. New patient spend scales with patient count. Acceptance scales with case value. On a practice doing high-ticket cosmetic work, moving acceptance a single point on the cases you already see can outrun a month of ad spend, because each point is attached to a five-figure case rather than a hygiene visit.

How do the two levers compare on cost, speed, and ceiling?

Here is the side-by-side, using the 2026 acquisition benchmarks above.

	Buy more new patients	Raise case acceptance
Cost to produce one more case	Roughly $312 per patient on average, up toward $1,800 in cosmetic specialties, before the patient has said yes	Near zero marginal cost per case, the patient and the diagnosis are already paid for
Time to result	Weeks to months, campaigns need to run and patients need to book	Days, it applies to the consults on next week's schedule
Capacity required	Open chair time and staff to see them	No added chair time, the appointments already exist
Ceiling	Limited by your market size and ad budget	Limited by how many cases you already diagnose
What fails first	Cost per acquisition climbs as you push volume	The consult itself, and it usually fails at the same point every time

The last row is the one worth sitting with. Both levers eventually run into a wall. The difference is that one wall is your market and your budget, and the other wall is a fixable moment in your own operatory.

When is new patient volume the right lever?

Sometimes it genuinely is, and a post that only argues one side is not useful to someone running a practice.

Buy volume when:

• You have real open chair time and a healthy acceptance rate. If you convert well and the schedule has gaps, the constraint is upstream and marketing is the correct answer.
• You are launching a new service line with no existing patient base. There is no unaccepted treatment to recover because you have not diagnosed any yet.
• You are recovering from attrition, a departing associate, or a relocation. You are rebuilding a patient base, not converting one.

The failure mode is buying volume when the schedule is full and acceptance is soft. That is paying premium prices for more people to say I want to think about it, which raises your cost per case without raising production. If acceptance is the leak, more patients means more leaking.

Where is the unaccepted treatment already hiding in your practice?

In three places, and most practices can find them in an afternoon.

Diagnosed and unscheduled treatment in the chart. What matters is not the total, it is the aging. Treatment diagnosed six months ago converts very differently from treatment diagnosed last week, and if you are not looking at it by month, you are treating a fresh case and a cold one the same way.

Consults that ended in I want to think about it. These are the most expensive patients in your database, because you paid full acquisition price and full diagnostic cost and collected nothing. Most were never systematically re-presented to, they just aged out of anyone's attention.

Partial acceptance. The patient said yes to the crown and stalled on the cosmetic portion. This is the quietest one, because the chart shows an accepted case and production looks fine. The high-value half is still sitting there.

Pull those three numbers before you approve another ad budget. It costs nothing to look.

What actually moves acceptance on high-ticket cosmetic cases?

Three things, and persuasion is not one of them.

Certainty. A patient cannot commit to a result they cannot picture. On cosmetic work especially, the gap between clinical language and what the patient imagines is where the decision dies. They are not weighing your treatment plan, they are weighing an outcome they are trying to visualize from a description.

The payment path presented as part of the plan. Cost is not an objection to overcome at the end, it is a condition of the decision. When paying is a rescue attempt after a no, it reads as pressure. Presented alongside the plan, it is just information the patient needs.

Timing. The decision is most likely while the patient is still in the room and still feeling what brought them in. Every day after that, competing priorities win.

This is the specific gap Smile PreVue is built for. It is a chairside iPad simulation the patient sees during the same visit, so the result stops being a description and becomes something they can look at while the decision is live. It runs on the practice's existing iPad with no added hardware, sets up in about 10 minutes, and covers 20-plus VITA shades. It is HIPAA compliant and BAA covered on Google Vertex AI.

On the payment side, a practice can price the plan chairside and let the patient pay in full by card or wallet, or pay over time through a financing partner via Stripe, subject to approval. Smile PreVue is not the lender. The patient's terms come from the provider.

It is worth naming the difference from the design suites here. Digital Smile Design and tools like it are excellent at what they are built for, which is planning and lab communication. That work happens before and after the consult. The acceptance lever lives inside the consult, in the operatory, while the patient is deciding. That is a different job, and it is where Smile PreVue is aimed.

Frequently asked questions

Is it cheaper to raise case acceptance or get more new patients? Raising acceptance, in almost every case. A new patient costs around $312 on average in 2026 and far more in cosmetic specialties, while converting an already-diagnosed case carries essentially no marginal acquisition cost.

What is a good case acceptance rate for a cosmetic practice? It depends heavily on case value and case mix, so the useful benchmark is your own trend rather than an industry average. Track acceptance by case value band. A practice can look healthy overall while converting poorly on exactly the high-ticket cases that matter most to production.

How much revenue is sitting in unaccepted treatment? Pull diagnosed-and-unscheduled treatment from your practice management software, aged by month, then add partially accepted plans where the cosmetic portion stalled. Most owners have not looked at that number recently, and it is usually larger than the marketing budget being debated.

Does showing the patient a simulation change acceptance? The mechanism is certainty. A patient who can see the outcome is making a decision about something concrete instead of imagining a result from clinical description. That is the moment most cosmetic consults are actually won or lost.

Do I need new hardware to run a chairside simulation? No. Smile PreVue runs on the iPad a practice already has, with about a 10-minute setup.

The takeaway

If production is soft, look at your own charts before you look at your ad budget. The most expensive patients in your practice are the ones you already paid to acquire and paid to diagnose, who left without deciding.

More patients is a real lever and sometimes the right one. It is just rarely the first one, and it is never the cheap one. If you want to understand the mechanics behind case acceptance before you spend another dollar on acquisition, start there.

You can see what a chairside simulation does to a cosmetic consult on your next case. Start a 3-day free trial from the App Store. No hardware to buy, about 10 minutes to set up.